Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has received a consensus rating of “Buy” from the twelve ratings firms that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $14.95.
KPTI has been the topic of a number of research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $18.00 price target on shares of Karyopharm Therapeutics in a report on Monday, May 15th. ValuEngine downgraded Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 25th. Robert W. Baird reiterated an “outperform” rating and set a $15.00 price target on shares of Karyopharm Therapeutics in a report on Tuesday, July 4th. Zacks Investment Research upgraded Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a report on Thursday, July 6th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $16.00 price target on shares of Karyopharm Therapeutics in a report on Friday, July 14th.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Voya Investment Management LLC increased its position in shares of Karyopharm Therapeutics by 42.1% in the second quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock worth $136,000 after buying an additional 4,444 shares during the period. Tudor Investment Corp ET AL purchased a new position in shares of Karyopharm Therapeutics during the second quarter worth approximately $136,000. Teza Capital Management LLC purchased a new position in shares of Karyopharm Therapeutics during the first quarter worth approximately $169,000. Trexquant Investment LP purchased a new position in shares of Karyopharm Therapeutics during the second quarter worth approximately $202,000. Finally, Metropolitan Life Insurance Co. NY increased its position in shares of Karyopharm Therapeutics by 12.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 21,911 shares of the company’s stock worth $206,000 after buying an additional 2,460 shares during the period. Hedge funds and other institutional investors own 57.58% of the company’s stock.
Shares of Karyopharm Therapeutics (KPTI) traded up 4.16% during mid-day trading on Wednesday, reaching $9.02. 73,182 shares of the company traded hands. Karyopharm Therapeutics has a 52-week low of $6.27 and a 52-week high of $14.63. The company’s 50 day moving average is $8.93 and its 200 day moving average is $9.91. The stock’s market capitalization is $425.18 million.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Tuesday, August 8th. The company reported ($0.64) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.64). Karyopharm Therapeutics had a negative return on equity of 70.42% and a negative net margin of 67,267.47%. During the same quarter in the prior year, the business earned ($0.84) EPS. The firm’s quarterly revenue was down 95.0% on a year-over-year basis. On average, equities analysts forecast that Karyopharm Therapeutics will post ($2.69) earnings per share for the current year.
WARNING: This news story was posted by BBNS and is the property of of BBNS. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://baseballnewssource.com/markets/karyopharm-therapeutics-inc-kpti-receives-average-rating-of-buy-from-brokerages/1536932.html.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with our FREE daily email newsletter.